Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Mayo/FDA meeting regarding guidance on patient-reported outcomes (PRO) Discussion, Education, and Operationalization FDA to release guidance for assessing.

Published byVincent Curtis Modified over 9 years ago

Similar presentations

Presentation on theme: "A Mayo/FDA meeting regarding guidance on patient-reported outcomes (PRO) Discussion, Education, and Operationalization FDA to release guidance for assessing."— Presentation transcript:

1

2 A Mayo/FDA meeting regarding guidance on patient-reported outcomes (PRO) Discussion, Education, and Operationalization FDA to release guidance for assessing PRO’s in all clinical trials (4th quarter 2005?) Meeting co-sponsored with FDA to: provide a focused process to facilitate discussion among all stakeholders educate stakeholders on background, content, and concerns provide an opportunity for input delineate ways to best operationalize the guidance into clinical trials February 23-25, 2006, DC (Westfields Marriott, Chantilly, VA, 7 miles from Dulles) FDA to release guidance for assessing PRO’s in all clinical trials (4th quarter 2005?) Meeting co-sponsored with FDA to: provide a focused process to facilitate discussion among all stakeholders educate stakeholders on background, content, and concerns provide an opportunity for input delineate ways to best operationalize the guidance into clinical trials February 23-25, 2006, DC (Westfields Marriott, Chantilly, VA, 7 miles from Dulles)

3 Mayo/FDA Meeting on PRO: Faculty Paper I: Conceptual Issues Margaret Rothman, Ph.D.Johnson & Johnson Joe Cappelleri, Ph.D.Pfizer Bonnie Teschendorf, Ph.D.American Cancer Society Joe Lipscomb, Ph.D.Emory University Philippe Beltram, Pharm.D.Sanofi-Aventis Paper II: PRO Instrument Selection Michelle Halyard, M.D.Mayo Clinic Scottsdale Dave Cella, Ph.D.Northwestern Claire Snyder, Ph.D.Johns Hopkins Maria Watson, Ph.D.GlaxoSmithKline Joseph Jackson, Ph.D.Bristol-Myers Squibb Paper III: PRO Instrument Development Issues Ralph Turner, Ph.D.Phase V Technologies Charles CleelandMD Anderson Bhash ParasuramanAstra Zeneca Lisa Rowenhorst, Pharm DAmgen Dr. Alexandra QuittnerUniversity of Miami

4 Mayo/FDA Meeting on PRO: Faculty Paper IV: PRO Validation Marlene Frost, Ph.D.Mayo Clinic Rochester Ron Hays, Ph.D.UCLA Joseph Stauffer, Ph.D.Alpharma Astra Liepa, PharmDEli Lilly & Company Bryce Reeve, Ph.D.National Cancer Institute Paper V: Interpretation of Results Based on PRO’s Jeff Sloan, Ph.D.Mayo Clinic Rochester Pennifer Erickson, Ph. D.Pennsylvania State Univ. Nancy Santanello, M.D.Merck Harry Guess, Ph.D.Univ. of North Carolina Dennis Revicki, Ph.D.MEDTAP International FDA response: Laurie Burke, Jane Scott, Donald Patrick et al Canadian Perspective: David Osoba, M.D. et al European Perspective: Neil Aaronson, Ph.D. et al

Download ppt "A Mayo/FDA meeting regarding guidance on patient-reported outcomes (PRO) Discussion, Education, and Operationalization FDA to release guidance for assessing."

Similar presentations

Clinical Significance for Quality of Life Endpoints in Clinical Trials FDA/Industry Statistics Workshop Washington, September 16, 2005 FDA/Industry Statistics.

Clinical Significance for Quality of Life Endpoints in Clinical Trials FDA/Industry Statistics Workshop Washington, September 16, 2005 FDA/Industry Statistics.
STANDARD IIC LIBRARY AND LEARNING RESOURCES The little standard that could.

STANDARD IIC LIBRARY AND LEARNING RESOURCES The little standard that could.
Responding to the Patient’s Voice: the importance of Patient Reported Outcomes Dr. Kirstie Haywood Senior Research Fellow RCN Research Institute, School.

Responding to the Patient’s Voice: the importance of Patient Reported Outcomes Dr. Kirstie Haywood Senior Research Fellow RCN Research Institute, School.
Interpreting of Patient-Reported Outcomes

Interpreting of Patient-Reported Outcomes
Faculty Learning Community for Understanding and Developing an Inclusive Campus Climate Jerry Sarquis, LC member, CELT FTA Ron Scott, LC facilitator, CELT.

Faculty Learning Community for Understanding and Developing an Inclusive Campus Climate Jerry Sarquis, LC member, CELT FTA Ron Scott, LC facilitator, CELT.
Current and Future Challenges in Designing Behavioral Interventions: From Randomized Trials to Community Implementation Current and Future Challenges in.

Current and Future Challenges in Designing Behavioral Interventions: From Randomized Trials to Community Implementation Current and Future Challenges in.
Methods used to assess and report pain-related endpoints in NDA 21-801 Ethan Basch, MD, MSc Center for Drug Evaluation and Research.

Methods used to assess and report pain-related endpoints in NDA Ethan Basch, MD, MSc Center for Drug Evaluation and Research.
The COSMIN study COnsensus-based Standards for the selection of health status Measurement INstruments Wieneke Mokkink, Caroline Terwee, Paul Stratford,

The COSMIN study COnsensus-based Standards for the selection of health status Measurement INstruments Wieneke Mokkink, Caroline Terwee, Paul Stratford,
A-1 Pravastatin-Aspirin Introduction Todd Baumgartner, MD, MPH Vice President Regulatory Sciences Pharmaceutical Research Institute Bristol-Myers Squibb.

A-1 Pravastatin-Aspirin Introduction Todd Baumgartner, MD, MPH Vice President Regulatory Sciences Pharmaceutical Research Institute Bristol-Myers Squibb.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
University of Delaware Problem-Based Learning: Experience It Yourself Institute for Transforming Undergraduate Education George Watson

University of Delaware Problem-Based Learning: Experience It Yourself Institute for Transforming Undergraduate Education George Watson
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
The Impact of IMMPACT Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia and Rheumatology Products Center for Drug Evaluation and Research.

The Impact of IMMPACT Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia and Rheumatology Products Center for Drug Evaluation and Research.
…patient reported outcome (PRO) measure for your clinical study Dr Keith Meadows, DHP Research & Consultancy Ltd.

…patient reported outcome (PRO) measure for your clinical study Dr Keith Meadows, DHP Research & Consultancy Ltd.
Quality of Life Research journal 2006+ Ron D. Hays Ph.D Editor-in-Chief Quality of Life Research

Quality of Life Research journal Ron D. Hays Ph.D Editor-in-Chief Quality of Life Research
Professional Standards 2009 Suzanne Scott, Ph.D., IDEC, ASID, Megan Scanlan, Director of Accreditation,

Professional Standards 2009 Suzanne Scott, Ph.D., IDEC, ASID, Megan Scanlan, Director of Accreditation,
NCI-sponsored treatment trials: CTCAE v4 790 individual items Standard Approach to AE Monitoring CATEGORYEXAMPLEDATA SOURCE LaboratoryNeutropeniaLaboratory.

NCI-sponsored treatment trials: CTCAE v4 790 individual items Standard Approach to AE Monitoring CATEGORYEXAMPLEDATA SOURCE LaboratoryNeutropeniaLaboratory.
Risa Hayes, PhD Research Advisor Eli Lilly and Company May 22, 2012.

Risa Hayes, PhD Research Advisor Eli Lilly and Company May 22, 2012.
A Regulatory Perspective on Electronic Data Capture

A Regulatory Perspective on Electronic Data Capture
Towards end-user centered outcome measurement: An example from Parkinson’s disease Peter Hagell, RN PhD Professor of Neurological Caring Science The PRO-CARE.

Towards end-user centered outcome measurement: An example from Parkinson’s disease Peter Hagell, RN PhD Professor of Neurological Caring Science The PRO-CARE.

Similar presentations

Ads by Google